natgillin/translations-raw huggingface dataset:
Week 52: ACR/EULAR Boolean Remission, n (%)
52. teden: ACR/EULAR remisija (Boolean), n (%)
Week 56
56.teden
week 64, Ultibro Breezhaler showed numerical improvement over glycopyrronium (1.95%; p=0.175) and statistical improvement over tiotropium (4.96%; p=0.001).
Po 64 tednih je zdravilo Ultibro Breezhaler doseglo absolutno višji odstotek takih dni v primerjavi z glikopironijem (za 1,95 %; p=0,175) ter statistično značilno višji odstotek takih dni v primerjavi s tiotropijem (za 4,96 %; p=0,001).
week 64, Xoterna Breezhaler showed numerical improvement over glycopyrronium (1.95%; p=0.175) and statistical improvement over tiotropium (4.96%; p=0.001).
Po 64 tednih je zdravilo Xoterna Breezhaler doseglo absolutno višji odstotek takih dni v primerjavi z glikopironijem (za 1,95 %; p=0,175) ter statistično značilno višji odstotek takih dni v primerjavi s tiotropijem (za 4,96 %; p=0,001).
Week 78/Last Observation
78. teden / zadnje opazovanje
Week 8-24
teden 8-24
Week 8-24
teden 8–24
Week 96 efficacy results
Rezultati učinkovitosti po 96 tednih
Week 96 window was between Day 630 and 713 (inclusive).
Okno v 96. tednu je med 630. in 713. dnevom (vključno z njima).
Week 96: 2.2% [-2.3%, 6.7%]
96. teden: 2,2% [-2,3%; 6,7%]
Week 96: 6.1% [0.3%, 12.0%]
96. teden: 6,1% [0,3%; 12,0%]
Week 96b
96. tedenb
Week 98 data for IMPACT includes combined placebo crossover and infliximab patients who entered the open-label extension
Podatki za 98. teden iz študije IMPACT vključujejo seštevek bolnikov, ki so prešli s placeba na infliksimab, in tiste bolnike na infliksimabu, ki so jih vključili v odprt podaljšek študije.
Week 98 data for IMPACT includes combined placebo crossover and infliximab patients who entered the open-label extension.
Podatki za 98. teden iz študije IMPACT vključujejo seštevek bolnikov, ki so prešli s placeba na infliksimab, in tiste bolnike na infliksimabu, ki so jih vključili v odprt podaljšek študije.
week in combination with
odmerek rifabutina.
Week number (w)*
Številka tedna (t)
Week number after last TREVICTA dose
Zadnji odmerek zdravila TREVICTA (teden 0)
Week Omalizumab or placebo administered
teden odmerjanje omalizumaba ali placeba
Week-14 responders (195/282) were analyzed for the primary endpoint, which was time from randomisation to loss of response (see Table 7).
Pri bolnikih z odzivom v 14. tednu (195/282) so analizirali primarni končni rezultat, ki je bil čas od randomizacije do izginotja odziva (glejte Preglednico 7).
Week1 (day 1-7):
1. teden (1.-7. dan):
Week2 (day 8-14):
2. teden (8.-14. dan):
Week3 (day 15-21):
3. teden (15.-21. dan):
Week4 (day 22-28):
4. teden (22.-28. dan):
Weekly
enkrat na teden
Weekly doses of up to 540 and
Med kliničnimi preskušanji so pri karcinomu ledvic dajali tedenske odmerke do
Weekly dosing in metastatic breast cancer
Tedensko odmerjanje pri metastatskem raku dojk
Weekly dosing in metatstatic breast cancer
Tedensko odmerjanje pri metastatskem raku dojk
Weekly during first month of therapy and during first month after dose modification.
prvi mesec zdravljenja in po spremembi odmerka enkrat na teden;
weekly for one month after initiation of the treatment
enkrat tedensko prvi mesec po uvedbi zdravljenja,
WEEKLY INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX)
TEDENSKA VMESNA ŠKATLA SKUPNEGA PAKIRANJA (BREZ "BLUE BOX" PODATKOV)
Weekly or monthly methods
Tedenske ali mesečne metode
Weeks 1 to 8
1. do 8. teden
Weeks 1, 2 & 3: Put on one patch and leave it on for exactly seven days.
1., 2. in 3. teden: namestite en obliž in ga nosite natanko sedem dni
Weeks 1-2
1. – 2. teden
Weeks 1-2: 400 mg (4 tablets of 100 mg) once daily
1. in 2. teden: 400 mg (4 tablete po 100 mg) enkrat na dan
weeks 18-25 in the absence of rescue therapies any time during the treatment period. b Overall platelet response is defined as achieving durable or transient platelet responses.
ugotovljeno 6- ali večkrat od 18. do 25. tedna študije brez uporabe rešilnih zdravil kadarkoli med zdravljenjem. b Celotni odziv trombocitov je opredeljen kot doseganje trajnega ali prehodnega odziva trombocitov.
Weeks 2 to 8
2. do 8. teden
Weeks 2, 4, 8, 12 and should be monitored closely at other time points, as clinically appropriate.
12. teden zdravljenja in jo skrbno spremljati, ko je klinično primerno.
Weeks 3 - 12
3. do 12. teden
Weeks 3-24: 200 mg (2 tablets of 100 mg) three times per week (with at least 48 hours between doses).
3. do vključno 24. teden: 200 mg (2 tableti po 100 mg) trikrat na teden (med posameznimi odmerki mora biti najmanj 48 ur).
Weeks 3-4
3. – 4. teden
Weeks 3–4
3. – 4. teden
Weeks 9 to 24
9. do 24. teden
weeks after first opening
tedne po prvem odprtju
weeks after first opening.
tedne po prvem odprtju
Weeks of treatment n = number of patients evaluable
tedni zdravljenja n = število bolnikov, primernih za ocenjevanje
Weeks ≥ 3
≥ 3. tedni
weeks)
tednov)
Wegener’s granulomatosis: Benepali is not recommended for the treatment of Wegener’s granulomatosis, a rare inflammatory disease.
Wegenerjeva granulomatoza: Zdravilo Benepali ni priporočljivo za zdravljenje redke vnetne bolezni Wegenerjeve granulomatoze.
Wegener’s granulomatosis: Enbrel is not recommended for the treatment of Wegener’s granulomatosis, a rare inflammatory disease.
Wegenerjeva granulomatoza: Zdravilo Enbrel ni priporočljivo za zdravljenje redke vnetne bolezni Wegenerjeve granulomatoze.
weigh 50 kg or more or have a body surface area above 1.25 square metres.
o so težki 50 kg ali več o ali katerih telesna površina je večja od 1,25 kvadratnega metra.
weigh 50 kg or more or have a body surface area above 1.25 square metres.
o težki 50 kg ali več ali katerih telesna površina je večja od 1,25 kvadratnega metra.
weigh less than 60 kg have a history of abnormal passageways (known as a fistula) between different organs in the body or from an organ to the skin
tehtate manj od 60 kg ste v preteklosti imeli nenormalne povezave (ki jim rečemo fistula) med različnimi organi v telesu ali med organom in kožo.
Weight
Telesna masa
Weight
telesna masa:
Weight (kg)
Telesna masa (v kg)
Weight (pVTEp orthopaedic surgery)
Telesna masa (pVTEp pri ortopedski operaciji)
Weight (SPAF, DVT/PE)
Telesna masa (SPAF, GVT/PE)
Weight [kg]
Telesna masa [kg]
Weight and levels of blood lipids and glucose may increase during antiretroviral therapy (see section 4.4).
Med protiretrovirusnim zdravljenjem se lahko povečajo telesna masa ter ravni lipidov in glukoze v krvi (glejte poglavje 4.4).
Weight at baseline (kg)
izhodiščna telesna masa (kg)
Weight decrease
hujšanje
weight decrease
zmanjšana telesna masa
weight decrease including decreased appetite
zmanjšanje telesne mase, tudi zmanjšan tek
weight decrease including decreased appetite, weight increase
zmanjšanje telesne mase, tudi zmanjšan tek, povečanje telesne mase
weight decrease including decreased appetite, weight increase
zmanjšanje telesne mase, tudi zmanjšan tek, zvečanje telesne mase
weight decrease, decrease of appetite
zmanjšanje telesne mase, zmanjšan apetit,
weight decrease, decreased appetite headache
zmanjšanje telesne mase, zmanjšan apetit glavobol
Weight decrease, increase appetite, anorexia
zmanjšanje telesne mase, povečanje apetita, anoreksija
weight decrease, increased appetite, uncontrolled loss of appetite (anorexia)
zmanjšanje telesne mase, povečanje apetita, nenadzorovana izguba apetita (anoreksija),
weight decrease, weight increase
zmanjšanje telesne mase, povečanje telesne mase
weight decrease, weight increase;
zmanjšanje telesne mase, povečanje telesne mase
Weight decreased
hujšanje
Weight decreased
zmanjša nje telesne mase
Weight decreased
zmanjšana telesna masa
Weight decreased
zmanjšanje telesne mase
Weight decreased
zmanšanje telesne mase
Weight decreased
znižana telesna masa
Weight decreased (G3/4: 0.2%)
ali zmanjšanje telesne mase (S3/4: 0,2 %)
Weight decreased , weight increase
zmanjšanje telesne mase, povečanje telesne mase
Weight decreased Blood creatinine phosphokinase increased Alanine aminotransferase increased
zmanjšanje telesne mase zvišanje kreatin-kinaze v krvi
Weight decreased Blood creatinine phosphokinase increased Alanine aminotransferase increased
zmanjšanje telesne mase zvišanje kreatin-kinaze v krvi zvišanje alanin- aminotransferaze
Weight decreased Decreased appetite
zmanjšanje telesne mase zmanjšan apetit
Weight decreased Fatigue
zmanjšanje telesne mase
Weight decreased Weight gain
zmanjšanje telesne mase povečanje telesne mase
Weight decreased**
telesne mase
Weight decreased**
v krvi** zmanjšanje telesne mase
Weight decreased**
zmanjšanje telesne mase
Weight decreased**,
zmanjšanje telesne
Weight decreased, Decreased appetite
zmanjšana telesna masa, zmanjšan tek
weight decreased, weight gain, anorexia
zmanjšanje telesne mase, povečanje telesne mase, anoreksija
weight decreased, weight gain, anorexia (loss of appetite), appetite increased
zmanjšanje telesne mase, povečanje telesne mase, anoreksija (izguba apetita), povečanje apetita;
Weight decreased, weight increase
prehranske motnje mase, povečanje telesne mase
Weight decreased, weight increase
zmanjšanje telesne mase, povečanje telesne mase
weight decreased, weight increased
zmanjšanje telesne mase, povečanje telesne mase
weight decreased, weight increased, liver function tests abnormal
zmanjšanje telesne mase, povečanje telesne mase, nenormalni testi delovanja jeter
Weight decreased/Weight loss
zmanjšanje telesne mase/izguba telesne mase
Weight decreased;
Povečanje telesne mase
Weight decreased; decreased appetite
zmanjšanje telesne mase, zmanjšan apetit
Weight decreased; G3/4 Blood bilirubin increased (9%)
zmanjšanje telesne mase, zvečanje bilirubina v krvi S3/4 (9 %)
weight decreased; weight increased; intolerance of alcohol; loss of appetite (anorexia or decreased appetite); dehydration;
zmanjšanje telesne mase, povečanje telesne mase, neprenašanje alkohola, izguba apetita (neješčnost ali zmanjšan apetit), dehidracija,
Weight decreasede, hepatic enzyme increasede (incl.
astenijo, splošnim slabim počutjem)
Weight fluctuation, decreased appetite
nihanje telesne mase, zmanjšanje apetita
Weight fluctuations, decreased appetite
nihanje telesne mase, zmanjšanje apetita,
weight gain
porast telesne mase,
Weight gain
Povečanje telesne mase
Weight gain
Povečanje telesne mase.
Weight gain
povečanje telesne mase1
Weight gain
povečanje telesne teže,
Weight gain
Povečevanje telesne mase
Weight gain
Pridobivanje telesne mase
Weight gain
Pridobivanje telesne mase.
weight gain
pridobivanje telesne teže
weight gain
pridobivanje telesne teže,
Weight gain
Zvečanje telesne mase
Weight gain 1
povečanje telesne mase1
weight gain fever
povečanje telesne mase vročina
Weight gain has been seen in patients taking Olanzapine Apotex.
Pri bolnikih, ki so jemali zdravilo Olanzapin Apotex, so opazili porast telesne teže.
Weight gain has been seen in patients taking OLANZAPINE CIPLA.
Pri bolnikih, ki so jemali zdravilo OLANZAPIN CIPLA, so opazili porast telesne mase.
Weight gain has been seen in patients taking Olanzapine Glenmark Europe.
Pri bolnikih, ki so jemali zdravilo Olanzapin Glenmark Europe, so opazili porast telesne teže.
Weight gain has been seen in patients taking Olanzapine Glenmark.
Pri bolnikih, ki so jemali zdravilo Olanzapin Glenmark, so opazili porast telesne mase.
Weight gain has been seen in patients taking Olanzapine Mylan.
Pri bolnikih, ki so jemali zdravilo OLANZAPIN MYLAN so opazili povečanje telesne mase.
Weight gain has been seen in patients taking Olanzapine Teva.
Pri bolnikih, ki so jemali zdravilo Olanzapin Teva, so opazili porast telesne teže.
Weight gain has been seen in patients taking Olazax Disperzi.
Pri bolnikih, ki so jemali zdravilo Olazax Disperzi, so opazili porast telesne mase.
Weight gain has been seen in patients taking Olazax.
Pri bolnikih, ki so jemali zdravilo Olazax, so opazili porast telesne mase.
Weight gain has been seen in patients taking Zalasta.
Pri bolnikih, ki so jemali zdravilo Zalasta, so opazili porast telesne teže.
Weight gain has been seen in patients taking ZYPADHERA.
Pri bolnikih, ki so jemali zdravilo ZYPADHERA, so opazili porast telesne mase.
Weight gain has been seen in patients taking ZYPREXA VELOTAB.
Pri bolnikih, ki so jemali zdravilo ZYPREXA VELOTAB, so opazili porast telesne mase.
Weight gain has been seen in patients taking ZYPREXA.
Pri bolnikih, ki so jemali zdravilo ZYPREXA, so opazili porast telesne mase.
Weight gain may occur during your treatment with Strensiq.
Pri bolniku se lahko telesna masa med zdravljenjem poveča.
weight gain numbness
povečanje telesne mase omrtvelost
weight gain stomach pain
povečanje telesne mase bolečina v trebuhu
weight gain,
povečanje telesne mase,
Weight gain, including a recommendation to monitor patients
povečanju telesne mase, vključno s priporočilom za nadziranje bolnikov,
weight gain, increased appetite, weight loss, decreased appetite
zvečanje telesne mase, povečan apetit, zmanjšanje telesne mase, zmanjšan apetit
weight gain, weakness, shortness of breath and fluid retention (symptoms of low blood protein levels)
zvišanje telesne mase, slabost, zasoplost in zastajanje tekočine (simptomi nizke ravni beljakovin v krvi),
weight gain, weight loss
povečanje telesne mase, zmanjšanje telesne mase,
weight gain, weight loss, anorexia;
povečanje telesne mase, hujšanje, neješčnost;
Weight gain.
zvečanje telesne mase
Weight gain.
Zvečanje telesne mase.
Weight gain1
Povečanje
Weight gain1
Povečanje telesne
Weight gain1
Povečanje telesne mase1
Weight gain5
porast telesne mase5
weight gain; increased appetite
povečanje telesne mase, večji apetit,
Weight gaina
povečanje telesne masea
Weight Group
kupina glede na telesno maso
Weight Groupa
kupina glede na telesno masoa
Weight had an effect on free aflibercept clearance and volume of distribution resulting with a 29% increase in aflibercept exposure in patients weighing ≥100 kg.
Telesna masa je vplivala na očistek in volumen porazdelitve prostega aflibercepta, tako da je bila pri bolnikih, ki so tehtali ≥ 100 kg, izpostavljenost afliberceptu 29 % večja.
Weight in kilograms
Telesna masa v kilogramih
weight increase
porast telesne mase
Weight increase
povečanje telesne mase
Weight increase
povečanje telesne mase,
weight increase
zvečanje telesne mase
Weight increase
zvečanje telesne mase,
Weight increase Blood creatine phosphokinase increased
povečanje telesne mase
Weight increase Creatine phosphokinase increased
Povečanje telesne mase Zvišanje kreatinin- fosfokinaze
Weight increase has been observed with INCRELEX treatment.
Pri zdravljenju z zdravilom INCRELEX so poročali o povečanju telesne mase.
weight increase or decrease
povečanje ali zmanjšanje telesne mase
weight increase or decrease,
povečanje ali zmanjšanje telesne mase
weight increase weight decrease
povečanje telesne mase zmanjšanje telesne mase
Weight increase*
zvečanje telesne mase
weight increase,
povečana telesna masa
weight increase, constipation, loss of appetite
povečanje telesne mase, zaprtje, izguba teka
weight increase, diabetes mellitus, dehydration, weight decrease, acidosis, fluid retention, hypercalcaemia, hypoproteinaemia
povečanje telesne mase, sladkorna bolezen, dehidracija, zmanjšanje telesne mase, acidoza, zastajanje tekočine, hiperkalciemija, hipoproteinemija
Weight increase, weight decrease
povečanje telesne mase, zmanjšanje telesne mase
Weight increase.
Povečanje telesne mase.
Weight increase.
zvečanje telesne mase
Weight increase.
zvečanje telesne mase,
Weight increased
MedDRA
Weight increased
povečanje telesne mase
Weight increased
zvečana telesna masa
Weight increased
zvečanje telesne mase
Weight increased (G3/4: 0%);
povečanje (S3/4 0 %)
Weight increased (G3/4: 0%); Weight decreased (G3/4: 0.2%)
zvečanje telesne mase (S3/4: 0 %) zmanjšanje telesne mase (S3/4:0,2 %)
Weight increased *, weight decreased*
povečanje telesne mase*, zmanjšanje telesne mase
Weight increased Increased appetite
povečana telesna masa, povečan apetit
Weight increased Increased appetite
povečanje telesne mase, večji apetit
Weight increased, increased appetite
zvišanje telesne mase, zvečan apetit
weight increased, increased appetite, weight decreased, decreased appetite
zvečana telesna masa, povečan tek, zmanjšana telesna masa, zmanjšan apetit
Weight increased, Weight decreased
povečana telesna masa, zmanjšana telesna masa
weight increased5
Motnje reproduk- cije in dojk
weight increased6
povečanje telesne mase6
weight increased8
povečanje telesne mase8
weight increased9
povečanje telesne mase9
Weight loss
Hujšanje
weight loss
hujšanje,
weight loss
izguba telesne mase
weight loss
izguba telesne mase,
weight loss
izguba telesne mase;
Weight loss
izguba teže
Weight loss
izgubo telesne mase
weight loss
zmanjšanje telesne mase
Weight loss
zmanjšanje telesne mase,
Weight loss (usually insignificant).
hujšanje (ponavadi nepomembno),
Weight loss aid
Zdravilo za zmanjševanje telesne mase
weight loss allergic reaction
izguba telesne mase,
Weight loss and general ill health (Cachexia)
izguba telesne mase in splošno slabo zdravje (kaheksija),
Weight loss and growth inhibition were very common during the treatment (at the end of treatment, mean decrease from baseline in weight and in height percentiles were of 15 percentiles and 8 percentiles, respectively) and growth velocity was inhibited (< 3rd percentile in 70 % of the patients).
Hujšanje in zastoj rasti sta bila zelo pogosta med zdravljenjem (ob koncu zdravljenja je znašalo povprečno zmanjšanje telesne mase 15 percentilov, višine pa 8 percentilov glede na osnovno vrednost ) in tudi njihova hitrost rasti je bila zmanjšana (pri 70 % bolnikov se je upočasnila za do 3 percentile).
Weight loss and loss of appetite (anorexia), tiredness, weakness
hujšanje in izguba teka (anoreksija), utrujenost, oslabelost,
Weight loss and loss of appetite (anorexia), tiredness, weakness.
Hujšanje in neješčnost (anoreksija), utrujenost; šibkost.
Weight loss and loss of appetite (anorexia); stomach pains; sore mouth, mouth ulcers or inflammation.
Izgubljanje telesne mase, izguba apetita (neješčnost), bolečine v želodcu, bolečine v ustni votlini in razjede ali vnetje ustne sluznice.
Weight loss and loss of appetite (anorexia); tiredness; weakness.
Hujšanje in izguba teka (neješčnost), utrujenost, šibkost.
Weight loss and loss of appetite (anorexia); tiredness; weakness.
hujšanje in neješčnost (anoreksija), utrujenost, šibkost;
weight loss and loss of appetite, feeling tired or weak
hujšanje in izguba teka, utrujenost oz. šibkost;
Weight loss at two years was 5.1 kg for patients who received ACOMPLIA 20 mg and 1.2 kg for placebo (Difference -3.8 kg; CI95% -4.4, -3.3; p< 0.001).
Zmanjšanje telesne mase po dveh letih je bilo pri bolnikih, ki so dobivali zdravilo ACOMPLIA 20 mg, 5,1 kg in pri bolnikih, ki so dobivali placebo, 1,2 kg (razlika –3,8 kg, IZ95 % –4,4, –3,3; p<0,001).
Weight loss at two years was 5.1 kg for patients who received ZIMULTI 20 mg and 1.2 kg for placebo (Difference -3.8 kg; CI95% -4.4, -3.3; p<0.001).
Zmanjšanje telesne mase po dveh letih je bilo pri bolnikih, ki so dobivali ZIMULTI 20 mg, 5,1 kg in pri bolnikih, ki so dobivali placebo, 1,2 kg (razlika –3,8 kg, IZ95 % –4,4, –3,3; p<0,001).
weight loss category
Kategorija izgube telesne teže
weight loss inability to resist the impulse to perform an action that is harmful involving excessive gambling, repetitive meaningless actions, binge eating, compulsive eating and compulsive shopping
zmanjšanje telesne mase nezmožnost upreti se impulzu po opravljanju določenih dejavnosti, ki so škodljive, vključno s pretiranim hazardiranjem, ponavljanjem nesmiselnih dejanj, prenajedanjem, kompulzivnim prehranjevanjem in kompulzivnim nakupovanjem
weight loss inability to resist the impulse to perform an action that is harmful involving excessive gambling, repetitive meaningless actions, binge eating, compulsive eating and compulsive shopping
zmanjšanje telesne mase nezmožnost upreti se impulzu po opravljanju določenih škodljivih dejavnosti, vključno s pretiranim hazardiranjem, ponavljanjem nesmiselnih dejanj, prenajedanjem, kompulzivnim prehranjevanjem in kompulzivnim nakupovanjem
weight loss inability to resist the impulse to perform an action that is harmful involving excessive gambling, repetitive meaningless actions, binge eating, compulsive eating and compulsive shopping
zmanjšanje telesne mase, nezmožnost upreti se impulzu po opravljanju določenih dejavnosti, ki so škodljive, vključno s pretiranim hazardiranjem, ponavljanjem nesmiselnih dejanj, prenajedanjem, kompulzivnim prehranjevanjem in kompulzivnim nakupovanjem.
Weight loss including decreased appetite
hujšanje, tudi zmanjšan tek,
Weight loss including decreased appetite
hujšanje, tudi zmanjšan tek;
Weight loss is potentially more serious in children (see section 4.4. Paediatric Population).
Izguba telesne mase je lahko pri otrocih bolj resna (glejte poglavje 4.4. Pediatrična populacija).
Weight loss is potentially more serious in children (see section 4.4. Paediatric population).
Izguba telesne mase je lahko pri otrocih resnejša (glejte poglavje 4.4. Pediatrična populacija).
weight loss kidney cyst (fluid-filled sac in the kidney)
izguba telesne mase, ledvična cista (vrečka v ledvicah napolnjena s tekočino).
weight loss kidney cyst (fluid-filled sac in the kidney)
izguba telesne mase, ledvična cista (vrečka v ledvicah, napolnjena s tekočino).
weight loss kidney cyst (fluid-filled sac in the kidney).
izguba telesne mase, ledvična cista (vrečka v ledvicah napolnjena s tekočino).
weight loss kidney cyst(fluid-filled sac in the kidney)
izguba telesne mase; ledvična cista (vrečka v ledvicah napolnjena s tekočino).
Weight loss may also affect the dose of medicines taken for other conditions (e.g. high cholesterol or diabetes).
Zaradi hujšanja je včasih treba prilagoditi odmerek zdravila, ki ga jemljete za zdravljenje drugih bolezenskih stanj (na primer zvišanega holesterola ali sladkorne bolezni).
Weight loss may be accompanied by an improvement in blood pressure and cholesterol levels.
Izguba telesne mase je lahko povezana z izboljšanjem krvnega tlaka in nivoja holesterola.
Weight loss of at least 5% baseline body weight was observed more frequently for subjects treated with naltrexone / bupropion (31%) compared to placebo (12%) (Table 3).
Zmanjšanje telesne mase za najmanj 5 % izhodiščne telesne mase so pri preiskovancih, zdravljenih z naltreksonom/bupropionom (31 %), opazili pogosteje kot pri uporabi placeba (12 %) (Preglednica 3).
Weight loss or extreme weight gain
izguba ali izjemno povečanje telesne mase,
weight loss pain and feeling numb in hands, feet or legs.
izguba telesne mase, bolečina in občutek otrplosti dlani, stopal ali nog.
weight loss weight increase.
izguba telesne mase zvečanje telesne mase.
weight loss which you cannot explain
hujšanje, ki ga ne znate pojasniti
weight loss,
hujšanje,
weight loss, dehydration, thirst, swelling of the lower legs, temperature change sensation, low calcium or sodium blood levels
hujšanje, dehidracija, žeja, otekanje spodnjih okončin, motnje v zaznavanju temperature, nizke vrednosti kalcija ali natrija v krvi
Weight loss, loss of appetite
izguba telesne mase, izguba teka,
Weight loss, loss of taste
hujšanje, izguba okusa
weight loss, weight gain
hujšanje, zvečanje telesne mase
weight loss, weight increase
zmanjšanje telesne mase, povečanje telesne mase
Weight loss.
izguba telesne mase
Weight loss.
zmanjšanje telesne mase
Weight loss;
izguba telesne mase,
Weight management and additional risk factors
Obvladovanje telesne mase in dodatni dejavniki tveganja
Weight Of Cat (kg)
Telesna masa mačke (kg)
Weight of cat [kg]
Teža mačke [kg]
Weight of dog (kg)
Telesna teža psa (kg)
Weight of Dog (kg)
Teža psa (kg)
Weight of Dog (kg))
Teža psa (kg)
Weight range
razpon telesne mase
Weight range of dog
Razpon mase psa (kg)
Weight should be monitored regularly e.g. at baseline, 4, 8 and 12 weeks after starting olanzapine treatment and quarterly thereafter .
Redno moramo spremljati telesno maso, npr. na začetku, 4, 8 in 12 tednov po začetku jemanja olanzapina in nato enkrat na tri mesece
Weight should be monitored regularly e.g. at baseline, 4, 8 and 12 weeks after starting olanzapine treatment and quarterly thereafter ..
Redno moramo spremljati telesno maso, npr. na začetku, 4, 8 in 12 tednov po začetku jemanja olanzapina in nato enkrat na tri mesece